OR WAIT null SECS
October 08, 2015.
The value of the multiple sclerosis therapeutics market is set for a slow rise (CAGR 1.5%) from $17.2 billion in 2014 to approximately $20 billion by 2024, according to research and consulting firm GlobalData.
The company’s latest report states that this growth will primarily be driven by the continued uptake of premium products and an increase in treatment rates as a result of the availability of novel alternatives.
The market is expected to plateau between 2018 and 2020 as the generic erosion of key branded products offsets the uptake of pipeline agents, but, says GlobalData analyst Thomas Parker, steady growth will resume from 2020 onwards, as additional pipeline products become available in western countries.